Klebsiella carbapenem-resistant enterobacteriaceae infection - Symptoms, Causes, Treatment & Prevention

```html

Overview

Klebsiella carbapenem‑resistant Enterobacteriaceae (CRE) refers to infections caused by the bacterium Klebsiella pneumoniae (or related Enterobacteriaceae) that have acquired resistance to carbapenem antibiotics—often considered “last‑line” drugs for serious Gram‑negative infections. These organisms are sometimes called “superbugs” because they are difficult to treat and can spread rapidly in healthcare settings.

• Who it affects: Primarily hospitalized patients, especially those in intensive care units (ICUs), long‑term care facilities, or who have undergone recent surgery. However, community‑acquired cases have been reported.
• Prevalence: In the United States, the CDC reported >13,000 CRE infections and >1,100 deaths in 2020, with Klebsiella species accounting for ~50 % of these cases.<sup>1</sup> Globally, incidence is rising, especially in regions with high antibiotic use such as Southern Europe, the Middle East, and parts of Asia.<sup>2</sup>

Symptoms

Symptoms vary depending on the organ system involved. Below is a complete list of common presentations, each accompanied by a brief description.

Respiratory Tract

• Pneumonia: Fever, chills, productive cough often with purulent or bloody sputum, shortness of breath, pleuritic chest pain.
• Ventilator‑associated pneumonia (VAP): New or worsening infiltrates on chest X‑ray plus fever, elevated white‑blood‑cell count, or increased secretions in intubated patients.

Urinary Tract

• Urinary tract infection (UTI): Dysuria, urgency, frequency, suprapubic pain, cloudy or foul‑smelling urine, possible flank pain if infection ascends.

Bloodstream

• Bacteremia/Sepsis: Fever, chills, hypotension, tachycardia, altered mental status, rapid breathing, organ dysfunction (e.g., elevated creatinine, jaundice).

Wound & Surgical Sites

• Surgical site infection: Redness, warmth, edema, purulent drainage, pain at incision site, possible dehiscence.

Other Sites

• Intra‑abdominal infection: Abdominal pain, tenderness, guarding, fever, nausea/vomiting.
• Skin & soft‑tissue infection: Cellulitis, abscess formation, erythema, warmth, pain.

Causes and Risk Factors

How the infection arises

Klebsiella becomes carbapenem‑resistant mainly through acquisition of genes that produce enzymes called carbapenemases (e.g., KPC, NDM, OXA‑48). These genes are often carried on plasmids, allowing rapid spread between bacteria.

Key risk factors

• Recent or prolonged hospitalization (≥5 days)
• ICU stay or mechanical ventilation
• Indwelling devices: urinary catheters, central venous catheters, tracheostomy tubes
• Recent broad‑spectrum antibiotic use, especially carbapenems, cephalosporins, or fluoroquinolones
• Immunosuppression (e.g., chemotherapy, transplant, HIV, steroids)
• Chronic medical conditions: diabetes, chronic kidney disease, lung disease
• Previous colonization or infection with CRE
• Living in long‑term care facilities

Diagnosis

Prompt and accurate diagnosis is critical because delays increase mortality (up to 50 % in septic patients). The diagnostic pathway includes:

Clinical assessment

• History of risk factors and symptom review
• Physical examination focused on likely infection source

Laboratory tests

• Blood cultures: Gold standard for bloodstream infection; at least two sets drawn from separate sites.
• Urine culture: Mid‑stream clean‑catch or catheter specimen for suspected UTI.
• Sputum or bronchoalveolar lavage (BAL): For pneumonia, especially in ventilated patients.
• Wound swab or tissue biopsy: For skin, surgical site, or intra‑abdominal infections.
• Carbapenem susceptibility testing: Performed by automated systems (e.g., VITEK 2) or manual broth microdilution; results reported as “susceptible,” “intermediate,” or “resistant.”
• Molecular testing: PCR or rapid multiplex panels to detect carbapenemase genes (KPC, NDM, VIM, OXA‑48). Many hospitals now use the Xpert Carba‑R assay for quick identification.

Imaging

• Chest X‑ray or CT for pulmonary involvement.
• Abdominal ultrasound/CT for intra‑abdominal abscesses.
• Ultrasound of catheterized sites if infection is suspected.

Treatment Options

Treatment must be individualized, guided by susceptibility results, infection severity, and patient comorbidities. Early consultation with an infectious disease specialist is strongly recommended.

Antibiotic regimens

• Polymyxins (colistin or polymyxin B): Often used despite nephrotoxicity; dose adjusted for renal function.
• Newer β‑lactam/β‑lactamase inhibitor combinations:
  • Ceftazidime‑avibactam – active against KPC‑producing strains.
  • Meropenem‑vaborbactam – FDA‑approved for CRE with KPC.
  • Imipenem‑relebactam – useful for certain carbapenemase‑negative CRE.
• Tigecycline: Good tissue penetration, but limited serum levels; often combined with another agent for bacteremia.
• Fosfomycin (IV): Occasionally added for synergistic effect.
• Combination therapy: Most experts recommend at least two active agents for serious infections to prevent emergence of further resistance.

Supportive care & procedures

• Source control: removal or replacement of infected catheters, drainage of abscesses, debridement of necrotic tissue.
• Hemodynamic support for septic patients (fluids, vasopressors).
• Renal replacement therapy if nephrotoxic drugs cause acute kidney injury.
• Infection control measures (contact precautions, hand hygiene) to stop spread within the facility.

Lifestyle & adjunctive measures

• Maintain adequate hydration and nutrition.
• Control blood glucose in diabetic patients.
• Avoid unnecessary antibiotics—ask providers about stewardship.

Living with Klebsiella carbapenem‑resistant Enterobacteriaceae infection

Even after the acute infection resolves, living with a history of CRE colonization can be challenging. Below are practical tips to manage daily life.

• Stay informed: Keep a copy of your microbiology report and share it with every new healthcare provider.
• Hand hygiene: Wash hands with soap and water for at least 20 seconds before eating, after using the bathroom, and after any contact with medical devices.
• Protective measures in hospitals: Request that staff use gloves and gowns (contact precautions) when caring for you.
• Device care: If you have a urinary catheter, central line, or feeding tube, follow strict cleaning protocols; report any redness, foul smell, or pain immediately.
• Medication adherence: Complete the full antibiotic course, even if you feel better. Use pill organizers or set phone reminders.
• Follow‑up labs: Schedule repeat cultures as advised (often weekly until clearance) and keep an eye on kidney and liver function tests if you received nephrotoxic drugs.
• Vaccinations: Stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines to reduce the chance of secondary infections.
• Support network: Join patient groups (e.g., CDC’s Antimicrobial Resistance Community) for emotional support and latest information.

Prevention

Because CRE spreads mostly in healthcare settings, prevention relies on strict infection‑control practices.

For healthcare facilities

• Active surveillance cultures (rectal swabs) for high‑risk units.
• Contact precautions (gloves, gowns, dedicated equipment).
• Environmental cleaning with EPA‑approved disinfectants.
• Antimicrobial stewardship programs to limit unnecessary carbapenem use.
• Prompt removal of unnecessary indwelling devices.

For patients and families

• Ask if your hospital follows CRE screening protocols.
• Never share personal items (towels, razors) with someone who is ill.
• Practice proper wound care at home; keep dressings clean and dry.
• Report any fever, chills, or new pain to your provider promptly.
• Limit exposure to sick individuals, especially in crowded settings.

Complications

If not promptly treated, CRE infections can lead to serious, sometimes fatal complications.

• Septic shock: Widespread inflammation causing dangerously low blood pressure and organ failure.
• Acute kidney injury: Often linked to both infection and nephrotoxic antibiotics.
• Respiratory failure: Severe pneumonia can require mechanical ventilation.
• End‑organ damage: Liver dysfunction, coagulopathy, or myocardial depression.
• Chronic colonization: Some patients remain carriers for months, increasing future infection risk and transmission to others.
• Mortality: Reported in‑hospital mortality ranges from 30 % to 70 % for bloodstream infections depending on patient factors and timely therapy.<sup>3</sup>

When to Seek Emergency Care

---

Sources:
1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2022.
2. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2023.
3. van Duin D, Doi Y. “The Epidemiology of Carbapenem‑Resistant Enterobacteriaceae.” Clin Microbiol Rev. 2020;33(2):e00153‑19. ```